View profile

FarmaKology Newsletter - Issue #23

Would you like to submit an article, some interesting news, or get your startup featured? Send whatev
FarmaKology Newsletter - Issue #23
By Abdul Menum Ali • Issue #23 • View online
Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to “abdul@farmakology.com”, and happy to have you featured on our newsletter (+1500 Subscribers ) !

Today's Startup
Carbiotix
Carbiotix was founded in 2014 as a spin-off company from the Department of Biotechnology at Lund University, Sweden, the largest university in the Nordic Region and a global top 100 university. The company’s soluble fiber ingredient AXOS was selected as a top new ingredient by the Nutrition Capital Network (NCN) in Europe and the US in 2015. In 2016, an Irish-based company called Pure Fiber Limited was formed to commercialize the AXOS technology.
News
ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the company’s recent program progress as well as a white paper analysis of Biogen’s October 22, 2019 decision to submit its amyloid-beta (Aβ)-targeting drug candidate, aducanumab for Alzheimer’s disease to the U.S. Food and Drug administration in early 2020.
IsoPlexis, the leading life sciences company in the single-cell proteomics space, announced today that it has received $2 million in grant funding from the National Cancer Institute’s Small Business Innovation Research Development Center for the advancement of intracellular proteomic pathway targeting solutions for single tumor cell analyses.
AbbVie Korea said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Rinvoq (Ingredient: upadacitinib), a once-daily selective and reversible Janus kinase (JAK) inhibitor treating rheumatoid arthritis.
Daewoong Pharmaceutical said that it has presented its phase 1 multiracial clinical trial for DWP14012, a gastroesophageal reflux disease (GERD) treatment candidate, during the United European Gastroenterology held in Barcelona, Spain.
Research & Study
Podcast
Ep. 70 - When Vaccine Court Turns Against The Victims The Vaccine Conversation With Melissa And Dr. Bob podcast
Job Opportunities
Upcoming Events
Video
Pneumococcal conjugate is one of the most cost-effective vaccines available: Ramanan Laxminarayan
Pneumococcal conjugate is one of the most cost-effective vaccines available: Ramanan Laxminarayan
Did you enjoy this issue?
Abdul Menum Ali

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".

If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue